Lv2
158 积分 2022-03-14 加入
The 2024 APLAR Consensus on the Management of Lupus Nephritis
2个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
3个月前
已完结
IgA nephropathy
3个月前
已完结
Shifting the SLE management paradigm: challenges and implications
3个月前
已完结
The global burden of SLE: prevalence, health disparities and socioeconomic impact
3个月前
已完结
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation
4个月前
已完结
Update on the pathophysiology and treatment of primary Sjögren syndrome
4个月前
已完结
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
4个月前
已完结
Dermatomyositis: Clinical features and pathogenesis
4个月前
已完结
The Type I Interferon Signature Reflects Multiple Phenotypic and Activity Measures in Dermatomyositis
4个月前
已完结
皖公网安备34019202002308
